News | August 06, 2025
Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
The company is focused on the development of novel treatments for RNA viruses
The US business faced price erosion due to increased competition.
Subscribe To Our Newsletter & Stay Updated
